By Fineline Cube Everest Medicines (HKG: 1985) announced today that its etripamil nasal spray has received marketing approval from China’s National Medical Products Administration (NMPA) for the acute treatment of paroxysmal supraventricular tachycardia (PSVT) in adults, with the goal of converting episodes back to sinus rhythm. The therapy will be commercialized under the brand name Cardamyst, marking the first self‑administered, rapid‑onset treatment option of its kind for PSVT patients in Greater China and a potential shift in how episodic cardiac events are managed — from the emergency room to the outpatient setting.
Regulatory Milestone
| Item | Detail |
|---|---|
| Agency | National Medical Products Administration (NMPA), China |
| Approval Type | Marketing authorization |
| Product | Etripamil nasal spray, branded Cardamyst |
| Indication | Acute treatment of paroxysmal supraventricular tachycardia (PSVT) in adults to convert to sinus rhythm |
| Approval Date | Sept 3, 2026 |
| Next Steps | Commercial launch and outpatient rollout across Greater China |
Drug Profile & Mechanism of Action
- Molecule: Etripamil, a novel chemical entity and the lead investigational product of Milestone Pharmaceuticals, Inc. (Nasdaq: MIST)
- Target / Class: Novel calcium channel blocker designed for rapid‑onset therapy in episodic cardiovascular conditions
- Innovation: Self‑administered nasal spray with the potential to transform patient care from emergency‑room management to an outpatient setting
- Licensing History: In May 2021, Ji Xing Pharmaceuticals secured exclusive rights from Milestone to develop and commercialize Cardamyst in Greater China
- Asset Transfer: In March 2026, Everest Medicines entered an asset purchase agreement with Ji Xing, acquiring rights to develop, commercialize, and locally manufacture Cardamyst in Greater China
Market Impact & Outlook
- Care‑model disruption: Cardamyst could redirect PSVT episode management away from costly emergency‑room visits toward rapid, patient‑self‑administered outpatient care
- First‑mover positioning: As a novel, self‑administered nasal therapy for acute PSVT conversion, Cardamyst enters Greater China with limited direct competition in its delivery format
- Strategic consolidation: The March 2026 acquisition from Ji Xing gives Everest Medicines full control of development, commercialization, and local manufacturing — strengthening supply‑chain and pricing flexibility
- Pipeline synergy: The approval adds a commercial‑stage cardiovascular asset to Everest Medicines’ portfolio and deepens its partnership track record with U.S. biotech Milestone Pharmaceuticals
Forward‑Looking Statements — This brief contains forward‑looking statements regarding the commercialization, market adoption, and potential impact of Cardamyst. Actual results may differ materially due to regulatory, competitive, manufacturing, and market risks. No investment decision should be made solely on the basis of this brief.-Fineline Info & Tech